<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371995</url>
  </required_header>
  <id_info>
    <org_study_id>LEI PDE 06 03</org_study_id>
    <nct_id>NCT00371995</nct_id>
  </id_info>
  <brief_title>Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar</brief_title>
  <official_title>The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banaras Hindu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rajendra Memorial Research Institute of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banaras Hindu University</source>
  <brief_summary>
    <textblock>
      Miltefosine and liposomal amphotericin B (AmBisome) are approved drugs for visceral&#xD;
      leishmaniasis. In this study both drugs will be given in a sequential manner. AmBisome will&#xD;
      be given on day 1, followed by Miltefosine for 14 days. Final Cure will be evaluated at six&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology Multicenter trial, eligible patients will be treated with Liposomal amphotericin&#xD;
      B (5 mg/kg) on day 1 and then with miltefosine capsules for 14 days (days 2-15).&#xD;
&#xD;
      At two weeks after the end of treatment the initial cure (clinical and parasitological cure)&#xD;
      and the clinical response will be determined. If initial cure is observed, a patient will be&#xD;
      evaluated after a 6 months (after end of treatment) follow up period for final clinical cure.&#xD;
&#xD;
      Number of patients planned Total number of patients planned: 150 patients at both centers&#xD;
      combined. 75 pediatric (2-11 years); 75 adult (12-65 years).&#xD;
&#xD;
      Lack of suitability for the trial:&#xD;
&#xD;
        -  Post Kala-azar Dermal Leishmaniasis (PKDL)&#xD;
&#xD;
        -  Concomitant treatment with other anti-leishmanial drugs&#xD;
&#xD;
        -  Any condition which compromises ability to comply with the study procedures&#xD;
&#xD;
      Administrative reasons:&#xD;
&#xD;
        -  Any condition or situation that compromises compliance with study procedures including&#xD;
           follow-up visit Study medication, dose and mode of administration Liposomal amphotericin&#xD;
           B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.&#xD;
&#xD;
      Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)&#xD;
&#xD;
      Dosage:&#xD;
&#xD;
        1. weighing â‰¥ 25 kg: 100 mg miltefosine daily as one capsule (50 mg) in the morning and one&#xD;
           capsule in the evening, after meals for 14 days.&#xD;
&#xD;
        2. weighing &lt; 25 kg: 50 mg miltefosine daily as one capsule (50 mg) in the morning, after&#xD;
           meals for 14 days. Parameter for evaluation&#xD;
&#xD;
             -  Final cure rate (initial parasite cure and clinical assessment at six month EOT)&#xD;
&#xD;
             -  Initial parasitological cure rate (based on splenic aspirates or Bone marrow&#xD;
                aspirate)&#xD;
&#xD;
             -  Clinical response at end of treatment (clinical assessment)&#xD;
&#xD;
             -  Adverse events&#xD;
&#xD;
      Statistical methods&#xD;
&#xD;
        -  Calculation of cure rate with 95% and 90% lower confidence limit according to Clopper&#xD;
           Pearson&#xD;
&#xD;
        -  Calculation of overall incidence of adverse events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final Cure six months after the end of treatment</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.&#xD;
Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B and Miltefosine</intervention_name>
    <description>Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.&#xD;
Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>AmBisome and Impavido</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female age between 2 and 65 years (inclusive)&#xD;
&#xD;
          -  Parasites visualized on splenic aspiration&#xD;
&#xD;
          -  Signs and symptoms compatible with visceral leishmaniasis (e.g. fever, splenomegaly,&#xD;
             anaemia, weight loss, leucopenia, thrombocytopenia)&#xD;
&#xD;
          -  Confirmed diagnosis of VL by visualization of parasites on splenic/bone marrow&#xD;
             aspirate&#xD;
&#xD;
          -  Fever for at least 2 weeks&#xD;
&#xD;
          -  Written informed consent from the patient/or from parent or guardian if under 18 years&#xD;
             old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin &lt; 6 g/dl&#xD;
&#xD;
          -  White blood cell count &lt; 1000/mm3&#xD;
&#xD;
          -  Platelets &lt;50,000&#xD;
&#xD;
          -  Prothrombin time &gt; 5 sec above control&#xD;
&#xD;
          -  ASAT &gt; 3 times the upper limit of normal&#xD;
&#xD;
          -  Serum creatinine or BUN &gt; 1.5 times the upper limit of normal&#xD;
&#xD;
          -  Malaria&#xD;
&#xD;
          -  Tuberculosis&#xD;
&#xD;
          -  HIV positive serology&#xD;
&#xD;
          -  Lactation, pregnancy&#xD;
&#xD;
          -  Refusing contraception method during treatment period plus 3 months&#xD;
&#xD;
          -  Any medical condition(s) that upon judgment of physician may affect the safety of the&#xD;
             patient when treated with study drugs&#xD;
&#xD;
          -  Any concomitant drug that is nephrotoxic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Sundar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banaras Hindu University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prabhat K Sinha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rajendra Memorial Research Institute of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kala-azar Medical Research Center</name>
      <address>
        <city>Muzaffarpur</city>
        <state>Bihar</state>
        <zip>842001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajendra Memorial Research Institute of Medical Sciences</name>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, Kumari P, Ravidas V, Chakravarty J, Verma N, Berman J, Ghalib H, Arana B. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2011 Feb;105(2):115-7. doi: 10.1016/j.trstmh.2010.10.008. Epub 2010 Dec 3.</citation>
    <PMID>21129762</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 5, 2006</study_first_submitted>
  <study_first_submitted_qc>September 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2006</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Shyam Sundar, Professor</name_title>
    <organization>Banaras Hdindu University</organization>
  </responsible_party>
  <keyword>Visceral leishmaniasis</keyword>
  <keyword>kala-azar</keyword>
  <keyword>miltefosine</keyword>
  <keyword>AmBisome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Miltefosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

